MTOR and urinary bladder carcinoma: The combination of olaparib and metformin can jointly inhibit the PI3K/Akt/mTOR signaling pathway and exert a synergistic antitumor effect, which provides an experimental basis for the combination of metformin and olaparib in the treatment of bladder cancer.